REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2021 >

Decisions 19th October 2021

At the meeting on the 19th October, the following decisions were agreed

 

New Drug Requests 

Approved

Aprepiptant (TLS Red)

  • For prevention of post-operative nausea and vomiting for patients attending adult anti-reflux surgery 

Toujeo Doublestar (TLS Amber no SCP)

  • for patients requiring >80 units per dose

Shared Care Protocols/TLS Status

Updated SCPs

Mycophenolate SCP updated to include dermatology and oral mucosal indications

Testosterone for testosterone replacement for male hypogonadism

Further Work

Prasugrel to be approved as TLS Amber 1 month for interventional neuroradiology operations, such as stent assisted coiling and flow diverter treatment once SCP updated and approved

Sativex for multiple sclerosis related moderate to severe spasticity- further work is needed before inclusion to the formulary.